Mirxes Holding Co Ltd
02629
Company Profile
Business description
Mirxes Holding Co Ltd is a miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, including Singapore and China. It has one Core Product (namely, GASTROClearTM), two other commercialized products (namely, LUNGClearTM and FortitudeTM), and six product candidates at the pre-clinical stage, as illustrated in the chart below. GASTROClearTM, its Core Product, is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. The company generates the majority of its revenue from Singapore.
Contact
2 Tukang Innovation Grove
No. 09-02 JTC MedTech Hub
Singapore618305
SGPT: +65 68162931
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
352
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.10 | 2.60 | 0.03% |
| CAC 40 | 7,743.93 | 34.12 | 0.44% |
| DAX 40 | 24,046.21 | 106.66 | -0.44% |
| Dow JONES (US) | 45,593.12 | 175.05 | 0.39% |
| FTSE 100 | 9,255.50 | 10.30 | -0.11% |
| HKSE | 25,201.76 | 323.16 | -1.27% |
| NASDAQ | 21,605.29 | 61.02 | 0.28% |
| Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,485.66 | 19.72 | 0.30% |
| S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
| SSE Composite Index | 3,800.35 | 68.03 | -1.76% |